[go: up one dir, main page]

ATE546440T1 - Organische verbindungen - Google Patents

Organische verbindungen

Info

Publication number
ATE546440T1
ATE546440T1 AT06839094T AT06839094T ATE546440T1 AT E546440 T1 ATE546440 T1 AT E546440T1 AT 06839094 T AT06839094 T AT 06839094T AT 06839094 T AT06839094 T AT 06839094T AT E546440 T1 ATE546440 T1 AT E546440T1
Authority
AT
Austria
Prior art keywords
organic compounds
compounds
organic
Prior art date
Application number
AT06839094T
Other languages
English (en)
Inventor
David Barnes
Gregory Raymond Bebernitz
Gary Mark Coppola
Katsumasa Nakajima
Travis Stams
Sidney Wolf Topiol
Thalaththani Ralalage Vedananda
James Richard Wareing
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37950917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE546440(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE546440T1 publication Critical patent/ATE546440T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06839094T 2005-12-08 2006-12-06 Organische verbindungen ATE546440T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74857305P 2005-12-08 2005-12-08
PCT/US2006/046545 WO2007067615A2 (en) 2005-12-08 2006-12-06 Thiadiazole derivatives as antidiabetic agents

Publications (1)

Publication Number Publication Date
ATE546440T1 true ATE546440T1 (de) 2012-03-15

Family

ID=37950917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06839094T ATE546440T1 (de) 2005-12-08 2006-12-06 Organische verbindungen

Country Status (26)

Country Link
US (1) US7700633B2 (de)
EP (1) EP1963292B1 (de)
JP (1) JP2009519248A (de)
KR (1) KR20080074969A (de)
CN (1) CN101326173A (de)
AR (1) AR056838A1 (de)
AT (1) ATE546440T1 (de)
AU (1) AU2006321905B2 (de)
BR (1) BRPI0619600A2 (de)
CA (1) CA2629857A1 (de)
CR (1) CR10049A (de)
EC (1) ECSP088506A (de)
ES (1) ES2381280T3 (de)
IL (1) IL191549A0 (de)
MA (1) MA30202B1 (de)
NO (1) NO20083031L (de)
NZ (1) NZ568243A (de)
PE (2) PE20100733A1 (de)
PL (1) PL1963292T3 (de)
PT (1) PT1963292E (de)
RU (1) RU2008127254A (de)
TN (1) TNSN08249A1 (de)
TW (1) TW200732315A (de)
UA (1) UA94724C2 (de)
WO (1) WO2007067615A2 (de)
ZA (1) ZA200804074B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
AU2006321904A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
US8119666B2 (en) * 2005-12-08 2012-02-21 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase)
WO2008067527A1 (en) * 2006-12-01 2008-06-05 Novartis Ag Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (es) * 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
JP7579057B2 (ja) * 2016-12-23 2024-11-07 ザ ユニバーシティー オブ クイーンズランド 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤
US20220073493A1 (en) * 2018-12-21 2022-03-10 Crystal Pharma, S.A.U. Process and intermediates for the preparation of voxelotor
KR20230074822A (ko) * 2019-03-14 2023-05-31 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
WO2021127586A1 (en) * 2019-12-20 2021-06-24 Calico Life Sciences Llc Protein tyrosine phosphatase degraders and methods of use thereof
CA3211545A1 (en) * 2021-03-11 2022-09-15 Liansheng Li Heterocycles and uses thereof
JP2024543452A (ja) * 2021-11-11 2024-11-21 カリコ ライフ サイエンシーズ エルエルシー プロテインチロシンホスファターゼ阻害剤及びその使用方法
EP4472957A1 (de) * 2022-02-02 2024-12-11 Nerio Therapeutics, Inc. Proteintyrosinphosphatasehemmer und verwendungen davon
AR128418A1 (es) * 2022-02-02 2024-05-08 Nerio Therapeutics Inc Inhibidores de la proteína tirosina fosfatasa y usos de estos
EP4472958A1 (de) * 2022-02-02 2024-12-11 Nerio Therapeutics, Inc. Proteintyrosinphosphatasehemmer und verwendungen davon
CN119790052A (zh) * 2022-09-13 2025-04-08 金橘生物科技公司 苯并稠合的n-杂环及其用途
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
CN118852335A (zh) * 2023-04-28 2024-10-29 中科中山药物创新研究院 噻二唑烷酮衍生物及其制备方法和应用
WO2025011570A1 (zh) * 2023-07-11 2025-01-16 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082841A1 (en) * 2002-04-03 2003-10-09 Novartis Ag 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
WO2004062664A1 (en) * 2002-12-30 2004-07-29 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
AU2006321904A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
US8119666B2 (en) * 2005-12-08 2012-02-21 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase)
US8084448B2 (en) * 2006-03-31 2011-12-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2007067615A2 (en) 2007-06-14
TW200732315A (en) 2007-09-01
EP1963292B1 (de) 2012-02-22
US20080262050A1 (en) 2008-10-23
AR056838A1 (es) 2007-10-24
KR20080074969A (ko) 2008-08-13
NO20083031L (no) 2008-08-28
CN101326173A (zh) 2008-12-17
CR10049A (es) 2008-08-25
PT1963292E (pt) 2012-05-10
ZA200804074B (en) 2009-03-25
EP1963292A2 (de) 2008-09-03
WO2007067615A3 (en) 2007-11-15
RU2008127254A (ru) 2010-01-20
AU2006321905B2 (en) 2011-08-11
PL1963292T3 (pl) 2012-07-31
US7700633B2 (en) 2010-04-20
AU2006321905A1 (en) 2007-06-14
MA30202B1 (fr) 2009-02-02
UA94724C2 (en) 2011-06-10
BRPI0619600A2 (pt) 2011-10-11
TNSN08249A1 (en) 2009-10-30
ECSP088506A (es) 2008-07-30
PE20071031A1 (es) 2007-11-15
CA2629857A1 (en) 2007-06-14
ES2381280T3 (es) 2012-05-24
NZ568243A (en) 2011-07-29
JP2009519248A (ja) 2009-05-14
PE20100733A1 (es) 2010-10-29
IL191549A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
ATE546440T1 (de) Organische verbindungen
ATE486862T1 (de) Organische verbindungen
ATE499363T1 (de) Organische verbindungen
BRPI0718874A2 (pt) Compostos orgânicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
EP2240028A4 (de) Organische verbindungen
ATE512953T1 (de) Heterocyclische verbindungen
DE602006018341D1 (de) Antihypercholesterinämische verbindungen
DE602005004925D1 (de) Lichtempfindliche organische vorrichtungen
CY2013047I2 (el) Ενωσεις διαρυλυδαντοϊνης
BRPI0718509A2 (pt) compostos orgânicos heterocíclicos
EP1874736A4 (de) Kondensierte heterocyclische verbindungen
EP1881543A4 (de) Organisches elektrolumineszenzelement
GB0500435D0 (en) Organic compounds
GB0500785D0 (en) Organic compounds
DE502005004675D1 (de) Organisches Bauelement
GB0505969D0 (en) Organic compounds
GB0502358D0 (en) Organic compounds
GB0505219D0 (en) Organic compounds
GB0503646D0 (en) Organic compounds
GB0504850D0 (en) Organic compounds
GB0507298D0 (en) Organic compounds
GB0504194D0 (en) Organic compounds
GB0504544D0 (en) Organic compounds